Among patients with heart failure and chronic kidney disease (CKD) that is not severe, mineralocorticoid receptor antagonists (MRAs) can prevent cardiovascular events. However, the effects of MRAs among patients with kidney failure necessitating…
Among patients with heart failure and chronic kidney disease (CKD) that is not severe, mineralocorticoid receptor antagonists (MRAs) can prevent cardiovascular events. However, the effects of MRAs among patients with kidney failure necessitating…